LONDON, April 19 (Reuters) - Britain's antitrust watchdogsaid on Friday that GlaxoSmithKline and three genericdrug companies had undermined competition by striking deals thatpaid the generic firms not to launch cheap copies of theantidepressant paroxetine.
The Office of Fair Trading alleged GSK concluded agreementswhich infringed competition law with each of Alpharma, Generics(UK) and Norton Healthcare over the supply of paroxetine - atop-selling medicine sold by GSK under the brand name Seroxat.